News
Video
Author(s):
Miguel-Angel Perales, MD, and Caron A. Jacobson, MD, share insights regarding the context and implications of the recent actions by the FDA to add boxed warnings to CAR T-cell therapies.
Blinatumomab Plus Consolidation Chemotherapy Extends OS in MRD– B-Cell Precursor ALL
Revisit the OncLive On Air Episodes From February 2024
Iopofosine I 131 Meets MRR End Point in R/R Waldenström Macroglobulinemia
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
Five-Year Follow-Up Data Confirm Long-Term Benefits of Olutasidenib in R/R IDH1+ AML
Odronextamab Elicits Durable Responses in Heavily Pretreated R/R Follicular Lymphoma
MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Dr Sabari on Barriers to Biomarker Testing in NSCLC
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC